- Home
- AMS vs CLRB Comparison
AMS vs CLRB Comparison
Compare AMS & CLRB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AMS | CLRB |
|---|---|---|
| Founded | 1980 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.8M | 12.9M |
| IPO Year | 1995 | 2008 |
Fundamental Metrics
Financial Performance| Metric | AMS | CLRB |
|---|---|---|
| Price | $2.10 | $2.87 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 1 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 6.8K | ★ 28.9K |
| Earning Date | 01-01-0001 | 06-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 230.00 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $19,714,000.00 | N/A |
| Revenue This Year | $3.81 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 0.81 | N/A |
| 52 Week Low | $2.02 | $0.23 |
| 52 Week High | $3.11 | $10.19 |
Technical Indicators
Market Signals| Indicator | AMS | CLRB |
|---|---|---|
| Relative Strength Index (RSI) | 45.26 | 39.39 |
| Support Level | $2.04 | $2.55 |
| Resistance Level | $2.19 | $3.60 |
| Average True Range (ATR) | 0.06 | 0.25 |
| MACD | -0.01 | -0.06 |
| Stochastic Oscillator | 27.75 | 11.33 |
Price Performance
Historical ComparisonAbout AMS American Shared Hospital Services
American Shared Hospital Services provides stereotactic radiosurgery equipment, Advanced radiation therapy, and related equipment. It currently provides Gamma Knife units to medical centers and stand-alone facilities. The company, along with its subsidiaries, operates through the following operations: Gamma Knife, Advanced Radiation Therapy Equipment and Services, and Proton Beam Radiation Therapy Operations. It generates most of its revenue from the domestic market.
About CLRB Cellectar Biosciences Inc.
Cellectar Biosciences Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of drugs for the treatment of cancer. The company's core objective is to leverage a proprietary phospholipid drug conjugate (PDC) delivery platform to develop PDCs that are designed to specifically target cancer cells and deliver improved efficacy and safety as a result of fewer off-target effects. It has one operating and reportable segment focused on utilizing its PDC platform to develop drugs for the treatment of cancer.